Guest Open Access Plus | Free Content | About | Sign in | New Users: Sign up | Mark List  

Reviews on Recent Clinical Trials(Online)

Volume 2 Issue 3
ISSN: 1574-8871
eISSN: 1876-1038

 

   All Titles

  Clinical Trials of Cancer Therapies Targeting Prostate-Specific Membrane Antigen
  pp.182-190 (9) Authors: William C. Olson, Warren D.W. Heston, Ayyappan K. Rajasekaran
 
 
      Abstract

Prostate cancer is the most common non-cutaneous cancer of men in the United States and represents their second-leading cause of cancer-related death. Metastatic disease is largely resistant to conventional chemotherapies, and targeted therapies are urgently needed. Prostate-specific membrane antigen (PSMA) is a prototypical cell-surface marker of prostate cancer. PSMA is an integral, nonshed, type 2 membrane protein with abundant and nearly universal expression in prostate carcinoma, but has limited extra-prostatic expression. In addition, PSMA is expressed in the neovasculature of other solid tumors. These findings have spurred development of PSMA-targeted therapies for cancer, and first-generation products have entered clinical testing. Vaccine approaches have included recombinant protein, nucleic acid and cell-based strategies, and anti-PSMA immune responses have been demonstrated in the absence of significant toxicity. Therapy with drug-conjugated and radiolabeled antibodies has yielded objective clinical responses as measured by reductions in serum prostate-specific antigen and/or imageable tumor volume. However, responses were observed in a minor fraction of patients and at doses near the maximum tolerated dose. Overall, these initial studies have provided measured proof of concept for PSMAbased therapies, and second-generation antibody and vaccine products may hold the key to exploit PSMA for molecularly targeted therapy of prostate and other cancers.

 
  Keywords: Prostate-specific membrane antigen, prostate cancer, immunotherapy, antibody-drug conjugate
  Affiliation: Nemours Center for Childhood Cancer Research, A.I. duPont Hospital for Children, 1600 Rockland Road, Wilmington, DE; USA.
 
  Key: New Content Free Content Open Access Plus Subscribed Content

Bentham Science Publishers
www.benthamscience.com

 

  Copyright © 1994 - 2014   Bentham Science Publishers